An engaging discussion with our expert panel:
Please note
The content within the recording of the Roundtable “Exploring the value that CD8 ImmunoPET may offer in drug pipeline development in immunotherapy clinical trials", that took place on March 31st 2022, has been made available for informational and educational purposes only. This information is only available to pharmaceutical and biotech personnel working on projects related to IO clinical trials.
The efficacy and safety of ImaginAb’s investigational CD8 ImmunoPET technology (zirconium Zr 89 crefmirlimab berdoxam) discussed during the Roundtable event have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation
